Tag: PFE

7 Hot Stocks That Look To Get Even Hotter In The New Year

| January 13, 2022
7 Hot Stocks That Look To Get Even Hotter In The New Year

These seven hot stocks could stay on fire throughout 2022 With the Fed’s latest moves raising concerns that the “everything bubble” has more room to deflate, hot stocks may seem like the last area you should invest in right now. Sentiment for crypto, tech stocks, and speculative growth plays may be shifting. But that doesn’t mean you should […]

Continue Reading

7 Dividend Stocks You Can Trust Your Retirement To

| March 30, 2021
7 Dividend Stocks You Can Trust Your Retirement To

Dividend investing isn’t sexy, but it’s still safer than buying risky spec plays Dividend investing is no longer as sexy as it used to be. The markets nowadays have gone hyperbolic. When most stocks are experiencing exponential capital appreciation, most investors are chucking dividend investing to the side. However, completely ignoring dividend stocks is not […]

Continue Reading

My 3 Favorite “Dogs Of The Dow” For 2019

| January 18, 2019 | 0 Comments
My 3 Favorite “Dogs Of The Dow” For 2019

The “Dogs of the Dow” is one of the simplest, most well-known dividend strategies on Wall Street. And investors who choose to jump in during 2019 will be shooting for their fifth straight year of market-beating returns. Of course, by being a little more selective, you and I can beat even the Dogs – just […]

Continue Reading

Next-Generation Medicine: Digital Therapeutics

| September 28, 2018 | 0 Comments
Next-Generation Medicine: Digital Therapeutics

Just last week I told you about the new version of its watch by Apple (Nasdaq: AAPL), which offers a bunch of health features, such as an EKG. The watch though is just the tip of the proverbial iceberg when it comes to how technology is changing medicine. One area that really has me excited is a new […]

Continue Reading

HALO Gearing Up For A Rebound In 2013?

| December 24, 2012 | 0 Comments
HALO Gearing Up For A Rebound In 2013?

Investors holding shares of biotech Halozyme Therapeutics (HALO) awoke to excellent news Friday morning.  The company announced it had entered into a worldwide collaboration and licensing agreement with Pfizer (PFE). The deal gives Pfizer a global license to develop and market products using Halozyme’s revolutionary Enhanze drug delivery technology.  I’ll tell you all about this […]

Continue Reading

A Few Ideas For Your Market Correction Buy List

| May 20, 2010 | 0 Comments

This past weekend I took my 13 and 9 year old daughters to Washington D.C.  It was their first visit to our nation’s capital.  And I couldn’t wait to show them all the sights. We did it all. We had a private tour of the Capitol.  We visited all the monuments on the Mall.  And […]

Continue Reading

Should You Still Hold Pfizer?

| December 28, 2009 | 0 Comments

A little over a year ago, I started buying shares of Pfizer (PFE). It was a scary time in the markets.  We’d just entered a major economic downturn.  The credit crisis was in full swing.  And the major market indices were falling fast. Despite the bearish conditions, I found a company I believed had long […]

Continue Reading

Is This Hedge Fund Strategy For You?

| February 9, 2009 | 0 Comments

As you may remember from my articles last week, every year I take a ski trip.  My skiing buddies are a group of well connected investment bankers, CEOs, and venture capitalists.  Two years ago we were in Vail.  Last year it was Telluride. This year, Aspen. After four days in the mountains, I was happy […]

Continue Reading

Pfizer Cuts The Dividend… Now What?

| January 26, 2009 | 0 Comments

The alarm went off early this morning.  It always does on Mondays.  Five more minutes I told myself… five more minutes.  The next thing I know I’m running late.  Damn snooze button.  I quickly jumped into the shower. Then, like always, I turn on CNBC.  I do it every morning when I’m getting ready. With […]

Continue Reading

An Undervalued Blue Chip

| November 7, 2008 | 0 Comments

Last Saturday morning I was sitting at the breakfast table reading the paper.  For me, it’s always the business section first.  The news was nothing new.  The same old rehashed commentary on the performance of the markets. I don’t need anyone to tell me October was a horrible month. You’ll note from peak to trough […]

Continue Reading